Gastro-Esophageal Reflux Disease
Conditions
Interventions
Twice per day divided administration method
Once per day administration method
Sponsors
Keiyu Hospital Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who have received upper GI endoscopic examination during 4 weeks before the clinical trial starts .Subjects who have not received two-fold dose administration of PPI during 4 weeks before the clinical trial starts Subjects who give informed consent by written from themselves or family members
Exclusion criteria
Exclusion criteria: Subjects who have any mental disorders Subjects who have histories of allergy against laperazol Subjects who have serious complications and problems to continue to perform this clinical trial Subjects who are pregnant, possibly pregnant, or feeding her children Subjects who cannot accept an upper GI endoscopic examination Subjects who have two-fold dose of PPI during 4 weeks before the clinical trial starts Subjects who are decided to be unacceptable for this clinical trial by their clinical physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of GERD symptoms,sleep disturbance and QOL | — |
Countries
Japan
Contacts
Public ContactAkira Mizuki
Keiyu Hospital Internal medicine
Outcome results
None listed